Details of the Drug

General Information of Drug (ID: DMU4T9Y)

Drug Name
Dimesna
Synonyms Tavocept (TN)
Indication
Disease Entry ICD 11 Status REF
Diabetic nephropathy GB61.Z Phase 3 [1]
Lung cancer 2C25.0 Phase 3 [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski):
0		 Molecular Weight 326.4
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 5
Hydrogen Bond Donor Count 0
Hydrogen Bond Acceptor Count 8
Chemical Identifiers
Formula
C4H8Na2O6S4
IUPAC Name
disodium;2-(2-sulfonatoethyldisulfanyl)ethanesulfonate
Canonical SMILES
C(CS(=O)(=O)[O-])SSCCS(=O)(=O)[O-].[Na+].[Na+]
InChI
InChI=1S/C4H10O6S4.2Na/c5-13(6,7)3-1-11-12-2-4-14(8,9)10;;/h1-4H2,(H,5,6,7)(H,8,9,10);;/q;2*+1/p-2
InChIKey
KQYGMURBTJPBPQ-UHFFFAOYSA-L
Cross-matching ID
PubChem CID
65625
CAS Number
16208-51-8
TTD ID
D05KZM
VARIDT ID
DR00091
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporter 1 (SLC22A6) DTQ23VB S22A6_HUMAN Substrate [3]
Organic anion transporter 3 (SLC22A8) DTVP67E S22A8_HUMAN Substrate [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts. Eur J Cancer. 2002 May;38(8):1148-56.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. J Clin Pharmacol. 2012 Apr;52(4):530-42.